Nkarta Begins Ntrust-1 Clinical Trial Of NKX019 In Lupus Nephritis, With The First Patient In Screening; Says IND Cleared For Ntrust-2

6/27/24 6:04:50 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NKTX alert in real time by email

The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease.

With this new IND, Nkarta plans to initiate Ntrust-2, an open-label, multi-center clinical trial of NKX019 for the treatment of systemic sclerosis (SSc, scleroderma), idiopathic inflammatory myopathy (IIM, myositis) and ANCA-associated vasculitis (AAV).

Clinical data from Ntrust-1 and Ntrust-2 planned for 2025.

Get the next $NKTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NKTX

Date	Price Target	Rating	Analyst
10/9/2024	$14.00	Buy	Rodman & Renshaw
8/14/2024	$16.00	Outperform → Strong Buy	Raymond James
3/22/2024	$13.00 → $16.00	Strong Buy → Outperform	Raymond James
12/22/2022		Outperform → Perform	Oppenheimer
10/10/2022	$25.00	Buy	Canaccord Genuity
7/28/2022	$26.00	Buy	Needham
7/18/2022	$30.00	Outperform	SVB Leerink
3/11/2022	$17.00	Outperform	Raymond James

More analyst ratings

$NKTX
Leadership Updates

Live Leadership Updates

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as
7/16/24 6:01:00 AM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
5/15/24 4:05:00 PM ET
$ENGN
$NAMS
$NKTX
$PCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and ICML 2023 meetingsClinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2
8/10/23 7:01:00 AM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care

$NKTX
Press Releases

Fastest customizable press release news feed in the world

Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare ConferenceNovember 19, 202410:55 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell ex
11/12/24 8:02:00 AM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash balance of $405.3 million on September 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical compa
11/7/24 4:02:00 PM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Nkarta to Participate in Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 10, 202412:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies
9/3/24 4:01:00 PM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil
10/17/23 7:01:00 AM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart
10/16/23 4:01:00 PM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic
6/27/23 7:01:00 AM ET
$NKTX
Biotechnology: Pharmaceutical Preparations
Health Care

Nkarta Begins Ntrust-1 Clinical Trial Of NKX019 In Lupus Nephritis, With The First Patient In Screening; Says IND Cleared For Ntrust-2

Chat with this insight

Recent Analyst Ratings for $NKTX

$NKTX Leadership Updates

Live Leadership Updates

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

$NKTX Press Releases

Fastest customizable press release news feed in the world

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in Upcoming Investor Conference

$NKTX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Nkarta, Maintains $23 Price Target

Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis

Nkarta shares are trading higher after the company appointed Nadir Mahmood as President.

$NKTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

$NKTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Nkarta with a new price target

Nkarta upgraded by Raymond James with a new price target

Nkarta downgraded by Raymond James with a new price target

$NKTX SEC Filings

$NKTX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$NKTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$NKTX Financials

Live finance-specific insights

SEC Form 10-Q filed by Nkarta Inc.

Nkarta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: Nkarta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

Officer Shook David gave a grant of 1,352 shares, decreasing direct ownership by 0.97% to 138,593 units (SEC Form 4)

SEC Form 4 filed by President Mahmood Nadir

New insider Mahmood Nadir claimed ownership of 31,376 shares (SEC Form 3)

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recent Analyst Ratings for
$NKTX

$NKTX
Leadership Updates

$NKTX
Press Releases

$NKTX
Market Insights

$NKTX
Large Ownership Changes

$NKTX
Analyst Ratings

$NKTX
SEC Filings

$NKTX
Insider Purchases

$NKTX
Insider Trading

$NKTX
Financials